9 assets in Large Cell Neuroendocrine Carcinoma

Therapeutic assets addressing Large Cell Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Large Cell Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Large Cell Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Large Cell Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
[203Pb]Pb-MP0712 Large Cell Neuroendocrine Carcinoma	Molecular Partners AG	P1/2	CCC (48)
[212pb]pb-mp0712 Large Cell Neuroendocrine Carcinoma	Molecular Partners AG	P1/2	CCC (48)
Atezolizumab Large Cell Neuroendocrine Carcinoma	Phanes Therapeutics	P1/2	CC (47)
Carboplatin Large Cell Neuroendocrine Carcinoma	Oncology Center of Biochemical Education And Research	P1/2	CC (47)
Etoposide Large Cell Neuroendocrine Carcinoma	Phanes Therapeutics	P1/2	CC (47)
Immunoglobulin H-Gamma1_L-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3) And Anti-[Homo Sapiens Dll3 (Delta-Like Ligand 3, Delta Like Canonical Notch Ligand 3)], Bispecific; Large Cell Neuroendocrine Carcinoma	Phanes Therapeutics	P1/2	CC (47)